Simranjeet Kaur Akshita and Amandeep Singh*

Department of Pharmaceutics, ISF College of Pharmacy, Punjab, India

*Corresponding Author: Amandeep Singh, Department of Pharmaceutics, ISF College of Pharmacy, Punjab, India.

Received: January 04, 2022; Published: February 01, 2022

Introduction

On 26 November 2021, WHO designated the variant B.1.1.529 a variant of concern, named Omicron, on the advice of WHO’s Technical Advisory Group on Virus Evolution (TAG-VE). This decision was based on the evidence presented to the TAG-VE that Omicron has several mutations that may have an impact on how it behaves, for example, on how easily it spreads or the severity of illness it causes.

References

1. Chen J., et al. “Omicron (B. 1.1. 529): Infectivity, vaccine breakthrough, and antibody resistance”. ArXiv (2021).
2. Rath SL., et al. “Scanning the RBD-ACE2 molecular interactions in Omicron variant”. bioRxiv (2021).
3. https://www.researchgate.net/publication/344564707_COVID19_Pandemic_Age_and_Temperature_Related_Effects
4. https://www.sinobiological.com/research/virus/hcov-spike-protein-overview
5. Venkata Krishnan AJ., et al. “Omicron variant of SARS-CoV-2 harbors a unique insertion mutation of putative viral or human genomic origin”.
6. https://www.cdc.gov/coronavirus/2019-ncov/variants/omicron-variant.html
7. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/scientific-brief-omicron-variant.html
8. https://www.bmj.com/content/375/bmj.n2943.long

Citation

Citation: Simranjeet Kaur Akshita and Amandeep Singh. “Omicron Variant: Characteristics and Interaction”. Acta Scientific Neurology 5.3 (2022): 01-04.

Copyright

Copyright: © 2022 Simranjeet Kaur Akshita and Amandeep Singh. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.